US OptionsDetailed Quotes

HUMA250516C2500

Watchlist

0.04
0.000.00%

15min DelayClose May 6 16:00 ET

0.00High0.00Low

Humacyte Stock Discussion

The Master Investor

May 2 21:48

Anyone thinking of investing in Themis company? It has caught my eye.

$Humacyte (HUMA.US)$

奶吧

Apr 23 10:09

$Humacyte (HUMA.US)$
seems to finds a stable supporrt level at 1.40
good for daytrade take profits

70156082

Apr 11 19:45

$Humacyte (HUMA.US)$ to silent here 😆 🤣 😂 😹

Darrow Fields

Apr 11 04:29

Sharing is caring...

$Humacyte (HUMA.US)$ Everybody, tell a friend to come on bye now!!

70156082

Apr 10 19:48

$Humacyte (HUMA.US)$ why no one here? 😆 🤣 😂 😹

Den the Dragon

Apr 9 21:52

$Humacyte (HUMA.US)$ 🤔

gamblingisfun3027

Apr 3 01:25

$Humacyte (HUMA.US)$ In for 3000 shares as a gamble, if they keep their FDA approval and get some revenue from Symvess could be an easy 2x or 3x from here. Stock's pretty cheap rn too
if FDA approval disappears then gg i guess

105699402

Mar 30 01:58

$Humacyte (HUMA.US)$ scam stock🖕

Teddy123

Mar 28 19:35

Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

$Humacyte (HUMA.US)$
Humacyte Q4 Earnings: 34 Hospitals Eye New FDA-Approved Vascular Treatment

Trytosaveabit

Mar 28 06:55

If I was CEO? I do believe I would retain counsel to see if Dr Lee’s comments to NYT was not only liable? But hurt the Company!

$Humacyte (HUMA.US)$ Humacyte CEO addresses concerns in NYT over FDA approval of Symvess
Investing.com -- Dr. Laura Niklason, President and CEO of Humacyte, Inc. (NASDAQ:HUMA), responded to a New York Times (NYSE:NYT) article that questioned the FDA’s approval of Symvess for commercial sales earlier this week. Niklason had previously withheld comment due to the company b...

No comment yet